https://orcid.org/0000-0001-5670-4443
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Coleman Rotstein, Joseph P. Lynch$suffix/text()$suffix/text() & George G. Zhanel. (2023) Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials. Expert Review of Anti-infective Therapy 21:11, pages 1213-1225.
Read now
Read now
Articles from other publishers (9)
George Zhanel, Melanie Baxter, Maggie Wong, Yazdan Mirzanejad, Anna Lee, Rita Dhami, Justin Kosar, Denise Werry, Neal Irfan, Jean-Francois Tessier, Gabriel Girourd, Carlo Tascini, Teagen Rolf von den Baumen, Andrew Walkty & James A. Karlowsky. (2023) Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry. Journal of Global Antimicrobial Resistance 33, pages 171-176.
Crossref
Crossref
Loandi Richter, Erika M. Du Plessis, Stacey Duvenage & Lise Korsten. (2023) Prevalence of extended-spectrum β-lactamase producing Enterobacterales in Africa's water-plant-food interface: A meta-analysis (2010–2022). Frontiers in Sustainable Food Systems 7.
Crossref
Crossref
Neveen A. Abdelaziz. (2022) Phenotype-genotype correlations among carbapenem-resistant Enterobacterales recovered from four Egyptian hospitals with the report of SPM carbapenemase. Antimicrobial Resistance & Infection Control 11:1.
Crossref
Crossref
Ashok Krishna, Tesfalem Zere, Sabyasachy Mistry, Omnia Ismaiel, Heather Stone, Leonard V. Sacks & James L. Weaver. (2022) Evaluation of a Sequential Antibiotic Treatment Regimen of Ampicillin, Ciprofloxacin and Fosfomycin against Escherichia coli CFT073 in the Hollow Fiber Infection Model Compared with Simultaneous Combination Treatment. Antibiotics 11:12, pages 1705.
Crossref
Crossref
Aamir Jamal Gondal, Nakhshab Choudhry, Hina Bukhari, Zainab Rizvi & Nighat Yasmin. (2022) Characterization of Genomic Diversity among Carbapenem-Resistant Escherichia coli Clinical Isolates and Antibacterial Efficacy of Silver Nanoparticles from Pakistan. Microorganisms 10:11, pages 2283.
Crossref
Crossref
Genara Romero Thomas, Alejandra Corso, Fernando Pasterán, Justina Shal, Aldo Sosa, Marcelo Pillonetto, Renata Tigulini de Souza Peral, Juan Carlos Hormazábal, Pamela Araya, Sandra Yamile Saavedra, Mariá Victoria Ovalle, María Antonieta Jiménez Pearson, Grettel Chanto Chacón, Eric Carbon, Carmen Julia Mazariegos Herrera, Selene del Carmen González Velásquez, Carolina Satan-Salazar, Fernando Villavicencio, Nancy Melgarejo Touchet, Sofía Busignani, Maritza Mayta-Barrios, Juan Ramírez-Illescas, Mariana López Vega, Cristina Mogdasy, Verónica Rosas, Nuris Salgado, Rodolfo Quiroz, Nathalie El-Omeiri, Marcelo Fabián Galas, Pilar Ramón-Pardo & Roberto Gustavo Melano. (2022) Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerging Infectious Diseases 28:11, pages 1-8.
Crossref
Crossref
John Philip Hays, Kazi Sarjana Safain, Mohammed Suliman Almogbel, Ihab Habib & Mushtaq Ahmad Khan. (2022) Extended Spectrum- and Carbapenemase-Based β-Lactam Resistance in the Arabian Peninsula—A Descriptive Review of Recent Years. Antibiotics 11:10, pages 1354.
Crossref
Crossref
Gian Maria Rossolini, Gregory Stone, Michal Kantecki & Francis F. Arhin. (2022) In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019. Journal of Global Antimicrobial Resistance 30, pages 214-221.
Crossref
Crossref
Alyssa R. Golden, Melanie R. Baxter, James A. Karlowsky, Laura Mataseje, Michael R. Mulvey, Andrew Walkty, Denice Bay, Frank Schweizer, Philippe R. S. Lagace-Wiens, Heather J. Adam & George G. Zhanel. (2022) Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance 4:1.
Crossref
Crossref